Locally advanced breast cancer: breast-conserving surgery and other factors linked to overall survival after neoadjuvant treatment
Frontiers in Oncology · 06.11.2023 · 13
DOI: 10.3389/fonc.2023.1293288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 06.11.2023. Verfasst von Gabriela Bezerra Nobrega und 11 weiteren Autor:innen. Beteiligte Einrichtung: Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Pa…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Recent data suggest that breast-conserving surgery (BCS) may positively impact overall survival (OS) in early breast cancer. However, the role of BCS in locally advanced breast cancer (LABC) following neoadjuvant therapy (NAT) remains uncertain.
Methods
We conducted a retrospective cohort study involving 530 LABC patients who underwent surgery after NAT between 2010 and 2015. Outcomes examined included OS, distant recurrence rates (DRR), and loco-regional recurrence rates (LRRs).
Results
Among the 927 breast cancer patients who received NAT, 530 were eligible for our study. Of these, 24.6% underwent BCS, while 75.4% underwent mastectomy (MS). The median follow-up duration was 79 months. BCS patients exhibited a higher pathological complete response (PCR) rate compared to those who underwent MS (22.3% vs. 10%, p < 0.001). The 6-year OS rates for BCS and MS were 81.5% and 62%, respectively ( p < 0.000). In multivariate OS analysis, MS was associated with worse outcomes (OR 1.678; 95% CI 1.069–2.635; p = 0.024), as was body mass index (BMI) (OR 1.031; 95% CI 1.006–1.058; p = 0.017), and stage IIIB or IIIC (OR 2.450; 95% CI 1.561–3.846; p < 0.000). Conversely, PCR (OR 0.42; 95% CI 0.220–0.801; p = 0.008) was associated with improved survival. DRR was significantly lower in BCS (15.4%) compared to MS (36.8%) (OR 0.298; 95% CI 0.177–0.504). LRRs were comparable between BCS (9.2%) and MS (9.5%) (OR 0.693; 95% CI 0.347–1.383).
Conclusion
Our findings suggest that BCS is oncologically safe, even for patients with large lesions, and is associated with superior OS rates compared to MS. Additionally, lower BMI, lower pretreatment stage, and achieving PCR were associated with improved survival outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Disciplina de Ginecologia, Departamento de Obstetrícia e Ginecologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
- Setor de Mastologia, Divisão de Ginecologia, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
- Departamento de Estatística e Matemática Aplicada, Universidade Federal do Ceará, Fortaleza, Brazil.
Zitieren
APA
Nobrega, G. B., Mota, B. S., de Freitas, G. B., Maesaka, J. Y., Mota, R. M. S., Goncalves, R., Trinconi, A. F., Ricci, M. D., Piato, J. R., Soares-Jr, J. M., Baracat, E. C., & Filassi, J. R. (2023). Locally advanced breast cancer: breast-conserving surgery and other factors linked to overall survival after neoadjuvant treatment. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1293288
Vancouver
Nobrega GB, Mota BS, de Freitas GB, Maesaka JY, Mota RMS, Goncalves R, et al. Locally advanced breast cancer: breast-conserving surgery and other factors linked to overall survival after neoadjuvant treatment. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1293288
BibTeX
@article{Nobrega2023,
author = {Nobrega, Gabriela Bezerra and Mota, Bruna Salani and de Freitas, Gabriela Boufelli and Maesaka, Jonathan Yugo and Mota, Rosa Maria Salani and Goncalves, Rodrigo and Trinconi, Angela Francisca and Ricci, Marcos Desidério and Piato, José Roberto and Soares-Jr, José Maria and Baracat, Edmund Chada and Filassi, José Roberto},
title = {Locally advanced breast cancer: breast-conserving surgery and other factors linked to overall survival after neoadjuvant treatment},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1293288}
}
EUVIMED